Drug Trial Radar · NCT04711252
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,371
Actual
Start
Jan 28, 2021
Primary completion
Jun 26, 2026
Study completion Feb 1, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.
Conditions
- ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833Drug
Dosage formulation: AZD9833 tablets will be administered orally
AnastrozoleDrug
Dosage formulation: Anastrozole tablets will be administered orally.
Anastrozole placeboDrug
Dosage formulation: anastrozole placebo tablets will be administrated orally.
AZD9833 placeboDrug
Dosage formulation: AZD9833 placebo tablets will be administrated orally.
PalbociclibDrug
Dosage formulation: palbociclib tablets/capsules will be administered orally
Luteinizing hormone-releasing hormone (LHRH) agonistDrug
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1Time frame: From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)
Locations
263 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama
Research Site
Springdale, Arkansas
Research Site
Harbor City, California
Research Site
Solvang, California
Research Site
Lone Tree, Colorado
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
West Palm Beach, Florida
Research Site
Indianapolis, Indiana
Research Site
Baton Rouge, Louisiana
Research Site
Silver Spring, Maryland
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
Hattiesburg, Mississippi
Research Site
Omaha, Nebraska
Research Site
Cincinnati, Ohio
Research Site
Cincinnati, Ohio
Research Site
Portland, Oregon
Research Site
West Columbia, South Carolina
Research Site
Sioux Falls, South Dakota
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
Tyler, Texas
Research Site
Fairfax, Virginia
Research Site
Kennewick, Washington
Research Site
Renton, Washington
Research Site
Morgantown, West Virginia
Research Site
Feldkirch, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Anderlecht, Belgium
Research Site
Edegem, Belgium
Research Site
Ghent, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Namur, Belgium
Research Site
Sint-Niklaas, Belgium
Showing 40 of 263 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.